Skip to content

Development of Endothelial Biomarkers

Development of Endothelial Biomarkers for Use in Cohort Studies. Comparison With Reference Biomarkers.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02006810
Acronym
NUTREND
Enrollment
50
Registered
2013-12-10
Start date
2013-07-31
Completion date
2017-09-19
Last updated
2018-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Syndrome

Keywords

Endothelium biomarkers, Atherosclerotic disease, Endothelial function, Nutritional stimuli

Brief summary

The main objective is to develop and validate new endothelial function markers discriminating and reproducible by assessing the ability to reveal changes in endothelial function in response to positive and negative nutritional stimuli.

Detailed description

The study will be randomized (on the order of taking the products: a single dose of lipids or a single dose of flavonoids), single-blinded, cross-over for each population (healthy and metabolic syndrome).

Interventions

BEHAVIORALInduction of endothelial function variations

Sponsors

University Hospital, Clermont-Ferrand
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
MALE
Age
40 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* \- 40 to 65 years old * male * non-smokers Specific inclusion criteria for healthy subjects : * Healthy subjects should not take antihypertensive or statin. * Healthy subjects should not present metabolic syndrome but one criterion of the metabolic syndrome will be tolerated. Specific inclusion criteria for subjects with metabolic syndrome : \- subjects with metabolic syndrome must have at least 3 of the 5 criteria associated with the metabolic syndrome.

Exclusion criteria

* treatment vasodilator nitric oxide liberating, * diabetes and coronary artery disease, * chronic alcoholism, * severe hepatic impairment, * end stage renal failure or dialysis, * neurological tremor, * cancer, mental illness or other severe disease which can impact informed consent and / or results, * Refusal to be registered in the National File of Volunteers * Person in exclusion of the National Volunteer File

Design outcomes

Primary

MeasureTime frameDescription
Flow Mediated Dilatation (FMD)compared to hyperemic velocity time integral (VTI) and endothelial microparticles (MPE)at 150 mn after the product intakeChanges in endothelial function from baseline at 150 mn after the product intake, evaluated by: \- Flow Mediated Dilatation (FMD) (reference) Compared to: * Hyperemic Velocity Time Integral (VTI) * Endothelial microparticles (MPE)

Secondary

MeasureTime frameDescription
Changes in endothelial function evaluated by cell adhesion molecule (CAM) and micro-RNA (miRNA)at 150 mn after the product intakeChanges in endothelial function from baseline at 150 mn after the product intake, evaluated by: * Cell Adhesion Molecule (CAM) * Micro-RNA (miRNA)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026